Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2021-11-29 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Syncona co-leads Series B financing in Quell
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated '29 November 2021'. It announces a specific corporate action: Syncona co-leading a Series B financing round for Quell Therapeutics, including details on committed capital, valuation uplift, and future ownership stake. This format—a brief, timely announcement of a significant corporate event (financing/investment) disseminated via the Regulatory News Service (RNS)—is characteristic of a general regulatory announcement that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Since it is a formal announcement distributed through the RNS system and doesn't detail comprehensive financial results or proxy materials, the most appropriate classification is the general regulatory filing category.
2021-11-29 English
Syncona appoints new Directors
Board/Management Information Classification · 99% confidence The document is an official announcement disseminated via RNS (RNS Number : 0422T) regarding the appointment of two new Non-Executive Directors, Dr Julie Cherrington and Dr Cristina Csimma, to the Board of Syncona Limited, effective February 1, 2022. This content directly relates to changes in the company's board of directors and senior management. This matches the definition for Board/Management Information (MANG). It is not a full annual report (10-K), an earnings release (ER), or a proxy statement (PSI).
2021-11-22 English
Achilles Presents Data at the SITC Annual Meeting
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange. The content is an announcement by Syncona Limited regarding data presented by its portfolio company, Achilles Therapeutics, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. This is a corporate update/news release disseminated via a regulatory news service. Since it is a specific announcement of corporate activity (data presentation) and not a full financial report (like 10-K or IR), nor a specific announcement like a dividend (DIV) or management change (MANG), it fits best under the general Regulatory Filings (RNS) category, which serves as a fallback for miscellaneous regulatory announcements distributed through this channel. The document length is substantial (14k+ chars), so it is not an RPA.
2021-11-12 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results for the six months ended 30 September 2021' for Syncona Limited. It contains substantive financial data, including net assets, NAV per share, and detailed operational/strategic reviews of the portfolio. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-11-11 English
Freeline reports new data and 3rd Quarter Results
Earnings Release Classification · 95% confidence The document is an RNS announcement from Syncona Limited, noting updates from its portfolio company, Freeline Therapeutics. The content details clinical trial progress (Fabry disease, Hemophilia B, Gaucher Type 1), pipeline outlook, appointment of a CMO, and importantly, reports financial results for the third quarter of 2021. The structure is that of a press release summarizing key operational and financial data, rather than the full, detailed financial report itself (like a 10-K or IR). Since it announces financial results for a period (Third Quarter Financial Results) and includes operational updates typical of an interim report, but is presented as a brief announcement (RNS format), it aligns best with an Earnings Release (ER) or potentially an Interim Report (IR). Given the explicit mention of 'Third Quarter Financial Results' and the format being a regulatory news service (RNS) announcement, 'ER' (Earnings Release) is the most precise fit for the initial announcement of period results. The document length is substantial (33k chars), suggesting it contains more than just a headline, but it is still framed as an RNS announcement, which often precedes the full 'IR' filing. Q3 2021
2021-11-10 English
Achilles reports Third Quarter Financial Results
Earnings Release Classification · 99% confidence The document is an RNS announcement from Syncona Limited, which is reporting on the Third Quarter 2021 Financial Results of its portfolio company, Achilles Therapeutics Plc. The text includes key financial highlights (Cash, R&D expenses, Net Loss) for the period ended September 30, 2021, and contains condensed consolidated balance sheets and statements of operations for Achilles. Since this is a comprehensive report detailing financial results for a period shorter than a year (Q3), it fits the definition of an Interim/Quarterly Report (IR). Although it is presented via an RNS, the core content is the quarterly financial report itself, not just an announcement of its publication (which would be RPA/RNS). The presence of detailed financial tables confirms it is the report content, not just a summary announcement. Q3 2021
2021-11-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.